<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Kripke DF</submitter><funding>NHLBI NIH HHS</funding><funding>NIMH NIH HHS</funding><pagination>42</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC1994947</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>7</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Although it has been claimed that insomnia causes an increased risk for depression, adequate controlled trials testing this hypothesis have not been available. This study contrasted the incidence of depression among subjects receiving hypnotics in randomized controlled trials versus those receiving placebo.&lt;h4>Methods&lt;/h4>The incidence of depression among patients randomized to hypnotic drugs or placebo was compiled from prescribing information approved by the United States Food and Drug Administration (FDA) and from FDA New Drug Application documents. Available data for zolpidem, zaleplon, eszopiclone, and ramelteon were accessed.&lt;h4>Results&lt;/h4>Data for 5535 patients randomized to a hypnotic and for 2318 randomized to placebo were compiled. The incidence of depression </pubmed_abstract><journal>BMC psychiatry</journal><pubmed_title>Greater incidence of depression with hypnotic use than with placebo.</pubmed_title><pmcid>PMC1994947</pmcid><funding_grant_id>R01 HL071123</funding_grant_id><funding_grant_id>R01 MH068545</funding_grant_id><funding_grant_id>MH68545</funding_grant_id><funding_grant_id>HL071123</funding_grant_id><funding_grant_id>R56 HL071123</funding_grant_id><pubmed_authors>Kripke DF</pubmed_authors></additional><is_claimable>false</is_claimable><name>Greater incidence of depression with hypnotic use than with placebo.</name><description>&lt;h4>Background&lt;/h4>Although it has been claimed that insomnia causes an increased risk for depression, adequate controlled trials testing this hypothesis have not been available. This study contrasted the incidence of depression among subjects receiving hypnotics in randomized controlled trials versus those receiving placebo.&lt;h4>Methods&lt;/h4>The incidence of depression among patients randomized to hypnotic drugs or placebo was compiled from prescribing information approved by the United States Food and Drug Administration (FDA) and from FDA New Drug Application documents. Available data for zolpidem, zaleplon, eszopiclone, and ramelteon were accessed.&lt;h4>Results&lt;/h4>Data for 5535 patients randomized to a hypnotic and for 2318 randomized to placebo were compiled. The incidence of depression </description><dates><release>2007-01-01T00:00:00Z</release><publication>2007 Aug</publication><modification>2025-04-21T23:44:31.834Z</modification><creation>2019-03-27T02:21:36Z</creation></dates><accession>S-EPMC1994947</accession><cross_references><pubmed>17711589</pubmed><doi>10.1186/1471-244X-7-42</doi></cross_references></HashMap>